Erratum: The role of FOXP3 in the development and metastatic spread of breast cancer (Cancer and Metastasis Reviews (2012) 31 (843-854) DOI 10.1007/s10555-012-9395-3));The role of FOXP3 in the development and metastatic spread of breast cancer

Cancer and Metastasis Reviews

Volumn 31, Issue 3-4, 2012, Pages 843-854

  Douglass, Stephen ^a   Ali, Simi ^a   Meeson, Annette P ^a   Browell, David ^a   Kirby, John A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; Chemokine; CXCR4; Epithelium; FOXP3; Metastasis

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LATS2 PROTEIN; MESSENGER RNA; MYC PROTEIN; PROTEIN P21; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BREAST CANCER; BREAST CARCINOGENESIS; CELLULAR DISTRIBUTION; DNA REPAIR; DNA SYNTHESIS; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REGULATORY T LYMPHOCYTE; REVIEW; X CHROMOSOME;

EID: 84867984352     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9417-9     Document Type: Erratum

References (87)

1. Wang, L.; et al. (2009). Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell, 16(4), 336-346.
2. Liu, R.; et al. (2009). FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Research, 69(6), 2252-2259.
3. Zuo, T.; et al. (2007). FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. The Journal of Clinical Investigation, 117(12), 3765-3773.
4. Zuo, T.; et al. (2007). FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell, 129(7), 1275-1286.
5. Li, W.; et al. (2011). Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers. Cancer Research, 71(6), 2162-2171.
6. Kaestner, K. H.; Knochel, W.; & Martinez, D. E. (2000). Unified nomenclature for the winged helix/forkhead transcription factors. Genes & Development, 14(2), 142-146.
7. Clark, K. L.; et al. (1993). Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature, 364(6436), 412-420.
8. Lopes, J. E.; et al. (2006). Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor. Journal of Immunology, 177(5), 3133-3142.
9. Weigel, D.; et al. (1989). The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell, 57(4), 645-658.
10. Coffer, P. J.; & Burgering, B. M. (2004). Forkhead-box transcription factors and their role in the immune system. Nature Reviews Immunology, 4(11), 889-899.
11. Lin, L.; & Peng, S. L. (2006). Coordination of NF-kappaB and NFAT antagonism by the forkhead transcription factor Foxd1. Journal of Immunology, 176(8), 4793-4803.
12. Hu, H.; et al. (2006). Foxp1 is an essential transcriptional regulator of B cell development. Nature Immunology, 7(8), 819-826.
13. Hong, H. K.; et al. (2001). The winged helix/forkhead transcription factor Foxq1 regulates differentiation of hair in satin mice. Genesis, 29(4), 163-171.
14. Hulander, M.; et al. (1998). The winged helix transcription factor Fkh10 is required for normal development of the inner ear. Nature Genetics, 20(4), 374-376.
15. Lai, C. S.; et al. (2001). A forkhead-domain gene is mutated in a severe speech and language disorder. Nature, 413(6855), 519-523.
16. Chatila, T. A.; et al. (2000). JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. The Journal of Clinical Investigation, 106(12), R75-R81.
17. Bennett, C. L.; et al. (2001). A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA- > AAUGAA) leads to the IPEX syndrome. Immunogenetics, 53(6), 435-439.
18. Bennett, C. L.; et al. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genetics, 27(1), 20-21.
19. Bennett, C. L.; & Ochs, H. D. (2001). IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Current Opinion in Pediatrics, 13(6), 533-538.
20. Sakaguchi, S. (2000). Regulatory T cells: Key controllers of immunologic self-tolerance. Cell, 101(5), 455-458.
21. Sakaguchi, S. (2005). Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunology, 6(4), 345-352.
22. Chen, G. Y.; et al. (2008). Cutting edge: Broad expression of the FoxP3 locus in epithelial cells: A caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. Journal of Immunology, 180(8), 5163-5166.
23. Karanikas, V.; et al. (2008). Foxp3 expression in human cancer cells. Journal of Translational Medicine, 6, 19.
24. Zheng, Y.; et al. (2007). Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature, 445(7130), 936-940.
25. Li, B.; et al. (2007). FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proceedings of the National Academy of Sciences of the United States of America, 104(11), 4571-4576.
26. Bettelli, E.; Dastrange, M.; & Oukka, M. (2005). Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proceedings of the National Academy of Sciences of the United States of America, 102(14), 5138-5143.
27. Rudensky, A. Y.; Gavin, M.; & Zheng, Y. (2006). FOXP3 and NFAT: Partners in tolerance. Cell, 126(2), 253-256.
28. Wu, Y.; et al. (2006). FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell, 126(2), 375-387.
29. Ziegler, S. F. (2006). FOXP3: Of mice and men. Annual Review of Immunology, 24, 209-226.
30. Bennett, C. L.; et al. (2000). X-Linked syndrome of polyendocrinopathy, immune dysfunction, and diarrhea maps to Xp11.23-Xq13.3. American Journal of Human Genetics, 66(2), 461-468.
31. Lal, G.; & Bromberg, J. S. (2009). Epigenetic mechanisms of regulation of Foxp3 expression. Blood, 114(18), 3727-3735.
32. Ebert, L. M.; et al. (2008). The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Research, 68(8), 3001-3009.
33. Lee, S. M.; Gao, B.; & Fang, D. (2008). FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1. Blood, 111(7), 3599-3606.
34. Allan, S. E.; et al. (2005). The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. The Journal of Clinical Investigation, 115(11), 3276-3284.
35. Yagi, H.; et al. (2004). Crucial role of FOXP3 in the development and function of human CD25 + CD4+ regulatory T cells. International Immunology, 16(11), 1643-1656.
36. Du, J.; et al. (2008). Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. Journal of Immunology, 180(7), 4785-4792.
37. Hancock, W. W.; & Ozkaynak, E. (2009). Three distinct domains contribute to nuclear transport of murine Foxp3. PLoS One, 4(11), e7890.
38. Banham, A. H.; et al. (2009). Monoclonal antibodies raised to the human FOXP3 protein can be used effectively for detecting Foxp3(+) T cells in other mammalian species. Veterinary Immunology and Immunopathology, 127(3-4), 376-381.
39. Mikami, Y.; et al. (2005). The functional region of CENP-H interacts with the Nuf2 complex that localizes to centromere during mitosis. Molecular and Cellular Biology, 25(5), 1958-1970.
40. Song, J. H.; Waataja, J. J.; & Martemyanov, K. A. (2006). Subcellular targeting of RGS9-2 is controlled by multiple molecular determinants on its membrane anchor, R7BP. Journal of Biological Chemistry, 281(22), 15361-15369.
41. Qian, X.; & Costa, R. H. (1995). Analysis of hepatocyte nuclear factor-3 beta protein domains required for transcriptional activation and nuclear targeting. Nucleic Acids Research, 23(7), 1184-1191.
42. Dowsland, M. H.; et al. (2003). Chemokines and breast cancer: A gateway to revolutionary targeted cancer treatments? Current Medicinal Chemistry, 10(7), 579-592.
43. Merlo, A.; et al. (2009). FOXP3 expression and overall survival in breast cancer. Journal of Clinical Oncology, 27(11), 1746-1752.
44. Zhang, H. Y.; & Sun, H. (2010). Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Letters, 287(1), 91-97.
45. Biyikoglu, B.; et al. (2009). Gingival crevicular fluid MMP-8 and -13 and TIMP-1 levels in patients with rheumatoid arthritis and inflammatory periodontal disease. Journal of Periodontology, 80(8), 1307-1314.
46. He, Y.; et al. (2007). Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clinical Cancer Research, 13(11), 3115-3124.
47. Wu, X.; et al. (2001). Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mechanisms of Development, 101(1-2), 61-69.
48. Hinz, S.; et al. (2007). Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Research, 67(17), 8344-8350.
49. Boumil, R. M.; & Lee, J. T. (2001). Forty years of decoding the silence in X-chromosome inactivation. Human Molecular Genetics, 10(20), 2225-2232.
50. Knudson, A. G.; Jr. (1971). Mutation and cancer: Statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America, 68(4), 820-823.
51. Woolf, C. M. (1960). An investigation of the familial aspects of carcinoma of the prostate. Cancer, 13, 739-744.
52. Xu, J.; et al. (1998). Evidence for a prostate cancer susceptibility locus on the X chromosome. Nature Genetics, 20(2), 175-179.
53. Slamon, D. J.; et al. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235(4785), 177-182.
54. Press, M. F.; et al. (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology, 15(8), 2894-2904.
55. Roy, V.; & Perez, E. A. (2009). Beyond trastuzumab: Small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. The Oncologist, 14(11), 1061-1069.
56. Nakayama, K. I.; & Nakayama, K. (2006). Ubiquitin ligases: Cell-cycle control and cancer. Nature Reviews. Cancer, 6(5), 369-381.
57. Sonoda, H.; et al. (2006). Significance of skp2 expression in primary breast cancer. Clinical Cancer Research, 12(4), 1215-1220.
58. Radke, S.; Pirkmaier, A.; & Germain, D. (2005). Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene, 24(21), 3448-3458.
59. Signoretti, S.; et al. (2002). Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. The Journal of Clinical Investigation, 110(5), 633-641.
60. Nakayama, K.; et al. (2004). Skp2-mediated degradation of p27 regulates progression into mitosis. Developmental Cell, 6(5), 661-672.
61. Grandori, C.; et al. (2000). The Myc/Max/Mad network and the transcriptional control of cell behavior. Annual Review of Cell and Developmental Biology, 16, 653-699.
62. Jung, P.; et al. (2008). AP4 encodes a c-MYC-inducible repressor of p21. Proceedings of the National Academy of Sciences of the United States of America, 105(39), 15046-15051.
63. Iavarone, A.; & Massague, J. (1997). Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature, 387(6631), 417-422.
64. Pinto, A. E.; et al. (2005). Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology, 37(1), 45-50.
65. Shiohara, M.; et al. (1994). Absence of WAF1 mutations in a variety of human malignancies. Blood, 84(11), 3781-3784.
66. el-Deiry, W. S.; et al. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75(4), 817-825.
67. Dulic, V.; et al. (1994). p53-Dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76(6), 1013-1023.
68. Somasundaram, K.; et al. (1997). Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature, 389(6647), 187-190.
69. Xiong, Y.; et al. (1993). p21 is a universal inhibitor of cyclin kinases. Nature, 366(6456), 701-704.
70. Cayrol, C.; Knibiehler, M.; & Ducommun, B. (1998). p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene, 16(3), 311-320.
71. Takahashi, Y.; et al. (2005). Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clinical Cancer Research, 11(4), 1380-1385.
72. Powzaniuk, M.; et al. (2004). The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Molecular Endocrinology, 18(8), 2011-2023.
73. Jiang, Z.; et al. (2006). Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neuroscience Research, 56(4), 450-458.
74. Jimenez-Velasco, A.; et al. (2005). Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia, 19(12), 2347-2350.
75. Zhao, B.; et al. (2007). Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes & Development, 21(21), 2747-2761.
76. Steinhardt, A. A.; et al. (2008). Expression of Yes-associated protein in common solid tumors. Human Pathology, 39(11), 1582-1589.
77. Bruce, J.; Carter, D. C.; & Fraser, J. (1970). Patterns of recurrent disease in breast cancer. Lancet, 1(7644), 433-435.
78. Campbell, J. J.; & Butcher, E. C. (2000). Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Current Opinion in Immunology, 12(3), 336-341.
79. Muller, A.; et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50-56.
80. Nasser, M. W.; et al. (2011). Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One, 6(9), e23901.
81. Harvey, J. R.; et al. (2007). Inhibition of CXCR4-mediated breast cancer metastasis: A potential role for heparinoids? Clinical Cancer Research, 13(5), 1562-1570.
82. Overbeck-Zubrzycka, D.; et al. (2010). FOXP3 regulates metastatic spread of breast cancer via control of expression of CXCR4 chemokine receptor. Cancer Prevention Research, 3(12).
83. Li, Y. M.; et al. (2004). Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell, 6(5), 459-469.
84. Mellor, P.; et al. (2007). Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. British Journal of Cancer, 97(6), 761-768.
85. Heinze, E.; et al. (2009). Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer cells in vitro and inhibits metastasis in vivo. International Journal of Oncology, 35(1), 167-173.
86. Jung, D. J.; et al. (2010). Foxp3 expression in p53-dependent DNA damage responses. Journal of Biological Chemistry, 285(11), 7995-8002.
87. Liu, Y.; et al. (2009). Activating transcription factor 2 and c-Jun-mediated induction of FoxP3 for experimental therapy of mammary tumor in the mouse. Cancer Research, 69(14), 5954-5960.